Pharmacology Discovery Services Taiwan, LTD.

Pharmacology Discovery Services Taiwan, LTD., a Taiwan-based for-profit corporate entity, develops and supplies preclinical murine models of bacterial and infectious diseases to the National Institute of Allergy and Infectious Diseases (NIAID) as a single-award prime contractor, with no subcontractor footprint and no set-aside designations across its federal work.

The vendor operates exclusively with NIAID under two parent IDIQ vehicles: the NIAID Preclinical Models of Infectious Diseases 2017-2024 contract (16 task orders, $16.5 million combined potential value) and the newer Pre-Clinical Models of Infectious Diseases IDIQ (3 task orders, $4.8 million combined potential value). The company's entire 21-award portfolio of $207.6 million combined potential value serves a single customer — NIAID's Division of Preclinical Innovation — with 100% concentration by agency and mission. Pharmacology Discovery Services Taiwan specializes in designing and producing specialized murine models that simulate bacterial infections, urinary tract infections caused by antibiotic-resistant pathogens, and other priority infectious disease models used to screen and evaluate medical countermeasures including therapeutics, vaccines, and diagnostics. Representative work includes a $2.3 million firm fixed-price delivery order awarded September 30, 2026, for therapeutic testing in murine models of bacterial infection with performance in Taiwan (ultimate completion September 29, 2027); a $1.9 million delivery order from July 15, 2024, for murine models of antibiotic-resistant urinary tract infection with Bethesda, Maryland performance; and a $621 thousand delivery order from July 22, 2026, for mouse models of Neisseria gonorrhoeae infection with Taiwan performance. The larger pre-clinical IDIQ awarded July 15, 2024, carries a $146.3 million ceiling and runs through July 14, 2031.

Activity shows volatility — two to four awards per year from 2021 through 2024, dropping to two awards in 2026 — with only one award ($2.3 million) facing completion in the next twenty-four months, limiting immediate recompete exposure. Service Contract Inventory records show SCI-reportable invoicing of $3.8 million total across FY2022–FY2025, with $1.2 million invoiced in FY2022 and $2.7 million in FY2025 supporting roughly 40 FTEs; FY2023 and FY2024 show zero reported invoiced revenue, suggesting delivery order activity without labor billing in those years. Median government-paid hourly rates on SCI-reportable prime contracts run consistently at $86.93 per hour across all percentiles. The vendor performs no subcontracting — 0% of hours across prime contracts are subcontracted — and the portfolio carries 100% obligation rate of zero percent, meaning $12 million of the $207.6 million potential value has been obligated to date, consistent with the IDIQ structure's indefinite delivery mechanism.